Walter Noordzij
dr.
In my profession as a nuclear medicine physician, I’m involved in both clinical and scientific applications of nuclear medicine and radiology modalities. My main interests include haematology, general oncology, radio-immunotherapy, and especially the implementation of new therapeutic strategies. Currently, I have a special interest in imaging post-transplant lymphoproliferative disease, as well as radio-immunotherapy in chemotherapy refractory (non)-Hodgkin’s lymphoma.
Effects of proton therapy on regional [18F]FDG uptake in non-tumor brain regions of patients treated for head and neck cancer
Published in: Clinical and Translational Radiation Oncology
Access to document
10.1016/j.ctro.2023.100652
document
Background and purpose: Previous pre-clinical research using [18F]FDG-PET has shown that whole-brain photon-based radiotherapy can affect brain glucose metabolism. This study, aimed to investigate how these findings translate into regional changes in brain [18F]FDG uptake in patients with head and neck cancer treated with intensity-modulated proton therapy (IMPT). Materials and methods: Twenty-three head and neck cancer patients treated with IMPT and available [18F]FDG scans before and at 3 months follow-up were retrospectively evaluated. Regional assessment of the [18F]FDG standardized uptake value (SUV) parameters and radiation dose in the...
A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making
Published in: EJNMMI Research
Access to document
10.1186/s13550-023-01024-y
document
BACKGROUND: Early detection of recurrent or progressive HCC remains the strongest prognostic factor for survival. Dual tracer PET/CT imaging with [11C]CH and [18F]FDG can further increase detection rates as both tracers entail different metabolic pathways involved in HCC development. We investigated dual-tracer PET/CT in clinical decision making in patients suspected of recurrent or progressive HCC. All HCC patients who underwent both [11C]CH and [18F]FDG PET/CT in our institute from February 2018 to December 2021 were included. Both tracer PET/CT were within 4 weeks of each other with at...
[15O]H2O PET: Potential or Essential for Molecular Imaging?
Published in: Seminars in Nuclear Medicine
Access to document
10.1053/j.semnuclmed.2023.08.002
document
Imaging water pathways in the human body provides an excellent way of measuring accurately the blood flow directed to different organs. This makes it a powerful diagnostic tool for a wide range of diseases that are related to perfusion and oxygenation. Although water PET has a long history, its true potential has not made it into regular clinical practice. The article highlights the potential of water PET in molecular imaging and suggests its prospective role in becoming an essential tool for the 21st century precision medicine in different...
Riemer H J A Slart, T Samara Martinez-Lucio, Hendrikus H Boersma, Ronald H Borra, Bart Cornelissen, Rudi A J O Dierckx, Magdalena Dobrolinska, Janine Doorduin, Paola A Erba, Andor W J M Glaudemans, Bruno Lima Giacobbo, Gert Luurtsema, Walter Noordzij, Joyce van Sluis, Charalampos Tsoumpas, Adriaan A Lammertsma
Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol
Published in: BMC Cancer
Access to document
10.1186/s12885-023-11280-9
document
Background: High dose unilobar radioembolization (also termed ‘radiation lobectomy’)—the transarterial unilobar infusion of radioactive microspheres as a means of controlling tumour growth while concomitantly inducing future liver remnant hypertrophy—has recently gained interest as induction strategy for surgical resection. Prospective studies on the safety and efficacy of the unilobar radioembolization-surgery treatment algorithm are lacking. The RALLY study aims to assess the safety and toxicity profile of holmium-166 unilobar radioembolization in patients with hepatocellular carcinoma ineligible for surgery due to insufficiency of the future liver remnant. Methods: The RALLY study...
Daan Andel, Marnix G.E.H. Lam, Joep de Bruijne, Maarten L.J. Smits, Arthur J.A.T. Braat, Adriaan Moelker, Erik Vegt, Simeon J.S. Ruiter, Walter Noordzij, Gianluca Grazi, Giulio E. Vallati, Roel J. Bennink, Otto M. van Delden, Onno W. Kranenburg, Jan N.M. Ijzermans, Maarten W. Nijkamp, Joris I. Erdmann, Rosa Sciuto, Jeroen Hagendoorn, Inne H.M. Borel Rinkes
External validation of 18 F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
Published in: Nuclear Medicine Communications
Access to document
10.1097/MNM.0000000000001707
document
OBJECTIVES: Detection of residual oesophageal cancer after neoadjuvant chemoradiotherapy (nCRT) is important to guide treatment decisions regarding standard oesophagectomy or active surveillance. The aim was to validate previously developed 18 F-FDG PET-based radiomic models to detect residual local tumour and to repeat model development (i.e. ‘model extension’) in case of poor generalisability. METHODS: This was a retrospective cohort study in patients collected from a prospective multicentre study in four Dutch institutes. Patients underwent nCRT followed by oesophagectomy between 2013 and 2019. Outcome was tumour regression grade (TRG) 1...
Maria J Valkema, Roelof J Beukinga, Avishek Chatterjee, Henry C Woodruff, David van Klaveren, Walter Noordzij, Roelf Valkema, Roel J Bennink, Mark J Roef, Wendy Schreurs, Michail Doukas, Sjoerd M Lagarde, Bas P L Wijnhoven, Philippe Lambin, John T M Plukker, J Jan B van Lanschot